Live Chat

交易 Vir Biotechnology VIR

出售
 購買

VirBiotechnology實時圖表

5m 15m 30m 1h 4h 1d 1w

金融工具基礎知識

Weekly Search
Weekly
Daily
日期  關閉 更改 更改(%)： 開倉 高 低

最新新聞

Christine Voong 2024 Dec 24, 10:19

美元匯率持續走高，聯準會鷹派立場支撐強勢；歐元及英鎊面臨壓力

Christine Voong 2024 Dec 24, 05:28

黃金價格走勢微幅上揚，美元強勢施壓，聯準會利率政策前景未明

Christine Voong 2024 Dec 24, 04:23

週二亞洲股市微幅上揚，美元強勢施壓全球市場，聯準會降息前景仍為關注焦點

So Ze Dong 2024 Dec 24, 01:00

週一科技股帶美股穩健上漲，分析師對於 “聖誕行情” 保持樂觀態度

Christine Voong 2024 Dec 23, 10:20

高通股價在贏得關鍵法律戰後上漲，市場前景明朗

Christine Voong 2024 Dec 23, 05:30

日本本田與日產合併消息提振市場，美國通膨數據放緩推動亞洲股市上漲

Christine Voong 2024 Dec 23, 03:00

美股指數期貨上揚，通膨降溫與聯準會利率前景牽動S&P 500指數、道瓊斯工業指數與納斯達克指數走勢

So Ze Dong 2024 Dec 23, 01:00

PCE通脹數據低於預期支撐美股指數大漲，市場對於「聖誕行情」維持樂觀態度

聯絡方式

點差

0.06

點差(%)

0.8108 %

槓桿

1:10

隔夜利息（買入）

-0.0597 %

隔夜利息（賣出）

-0.0292 %

貨幣

USD

交易時間

市場關閉

星期四

14:31 - 20:59

星期一

14:31-20:59

星期二

14:31-17:59

星期五

14:31-20:59

分析與統計

開倉

---

上一次平倉

---

52 週高點/低點

--- – ---

市值

1010864832

流通股份

137720000

收益日期（下一個）

0000-00-00

現金殖利率 

除息日

遠期年股息率

0

遠期年現金殖利率

0

每股盈餘

-3.93

了解有關此金融工具的詳細資訊

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

相關工具

資產
出售
購買
更改(%)：

立即交易

立即交易

立即交易

立即交易
查看所有金融工具
Trustpilot
Live Chat